€165M
The financing from Sofinnova Partners and Old College Capital will support the launch of precision fibrosis therapeutics.
Forth Therapeutics
Forth Therapeutics develops next-generation precision treatments for fibrosis.
€165MTotal raised
Forth Therapeutics is a biotechnology company advancing precision medicines for fibrosis across multiple organ systems. Operating from Edinburgh and Cambridge, the business builds on academic research from the University of Edinburgh.
Categories
Team
AL
Alex Leech
CEO
NH
Neil Henderson
Chair of Tissue Repair and Regeneration at the University of Edinburgh